Item 2.02. Results of Operations and Financial Condition.

On November 3, 2021, Lumos Pharma, Inc., a Delaware corporation (the "Company"), issued a press release providing an operational update and reporting results for the third quarter ended September 30, 2021 ("Press Release").

A copy of the Press Release and the Third Quarter 2021 Financial Results Presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

The information in this Current Report, including Exhibits 99.1 and 99.2 attached hereto are furnished under Item 2.02 of this report and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

--------------------------------------------------------------------------------



Item 9.01.       Financial Statements and Exhibits.

(d)  Exhibits.

Exhibit Number                                              Description
                            Press Release, dated November 3, 2021, entitled "  Lumos Pharma Reports
        99.1                Third Quarter 2021 Financial Results and Provides Clinical and Corporate
                            Updates  "
        99.2                  Third Quarter 2021 Financial Results Presentation



--------------------------------------------------------------------------------

© Edgar Online, source Glimpses